Antiarrhythmic	antiarrhythmic	O	O
plasma	plasma	O	O
concentrations	concentrations	O	O
of	of	O	O
cibenzoline	cibenzoline	O	O
on	on	O	O
canine	canine	O	O
ventricular	ventricular	O	O
arrhythmias	arrhythmias	O	O
.	.	O	O

Using	using	O	O
two-stage	two-stage	O	O
coronary	coronary	O	O
ligation-	ligation-	O	O
,	,	O	O
digitalis-	digitalis-	O	O
,	,	O	O
and	and	O	O
adrenaline-induced	adrenaline-induced	O	O
canine	canine	O	O
ventricular	ventricular	O	O
arrhythmias	arrhythmias	O	O
,	,	O	O
antiarrhythmic	antiarrhythmic	O	O
effects	effects	O	O
of	of	O	O
cibenzoline	cibenzoline	O	O
were	were	O	O
examined	examined	O	O
and	and	O	O
the	the	O	O
minimum	minimum	O	O
effective	effective	O	O
plasma	plasma	O	O
concentration	concentration	O	O
for	for	O	O
each	each	O	O
arrhythmia	arrhythmia	O	S_disease
model	model	O	O
was	was	O	O
determined	determined	O	O
.	.	O	O

Cibenzoline	cibenzoline	O	O
suppressed	suppressed	O	O
all	all	O	O
the	the	O	O
arrhythmias	arrhythmias	O	O
,	,	O	O
and	and	O	O
the	the	O	O
minimum	minimum	O	O
effective	effective	O	O
plasma	plasma	O	O
concentrations	concentrations	O	O
for	for	O	O
arrhythmias	arrhythmias	O	O
induced	induced	O	O
by	by	O	O
24-h	24-h	O	O
coronary	coronary	O	O
ligation	ligation	O	O
,	,	O	O
48-h	48-h	O	O
coronary	coronary	O	O
ligation	ligation	O	O
,	,	O	O
digitalis	digitalis	O	O
,	,	O	O
and	and	O	O
adrenaline	adrenaline	S_chemicals	O
were	were	O	O
1.9	1.9	O	O
+	+	O	O
/-	/-	O	O
0.9	0.9	O	O
(	(	O	O
by	by	O	O
8	8	O	O
mg/kg	mg/kg	O	O
i.v	i.v	O	O
.	.	O	O
)	)	O	O
,	,	O	O
1.6	1.6	O	O
+	+	O	O
/-	/-	O	O
0.5	0.5	O	O
(	(	O	O
by	by	O	O
8	8	O	O
mg/kg	mg/kg	O	O
i.v	i.v	O	O
.	.	O	O
)	)	O	O
,	,	O	O
0.6	0.6	O	O
+	+	O	O
/-	/-	O	O
0.2	0.2	O	O
(	(	O	O
by	by	O	O
2	2	O	O
mg/kg	mg/kg	O	O
i.v	i.v	O	O
.	.	O	O
)	)	O	O
,	,	O	O
and	and	O	O
3.5	3.5	O	O
+	+	O	O
/-	/-	O	O
1.3	1.3	O	O
(	(	O	O
by	by	O	O
5	5	O	O
mg/kg	mg/kg	O	O
i.v	i.v	O	O
.	.	O	O
)	)	O	O
micrograms/ml	micrograms/ml	O	O
,	,	O	O
respectively	respectively	O	O
(	(	O	O
mean	mean	O	O
+	+	O	O
/-	/-	O	O
SDM	sdm	O	O
,	,	O	O
n	n	O	O
=	=	O	O
6	6	O	O
-	-	O	O
7	7	O	O
)	)	O	O
.	.	O	O

The	the	O	O
concentration	concentration	O	O
for	for	O	O
adrenaline-induced	adrenaline-induced	O	O
arrhythmia	arrhythmia	O	S_disease
was	was	O	O
significantly	significantly	O	O
higher	higher	O	O
than	than	O	O
those	those	O	O
for	for	O	O
the	the	O	O
other	other	O	O
types	types	O	O
of	of	O	O
arrhythmias	arrhythmias	O	O
.	.	O	O

This	this	O	O
pharmacological	pharmacological	O	O
profile	profile	O	O
is	is	O	O
similar	similar	O	O
to	to	O	O
those	those	O	O
of	of	O	O
mexiletine	mexiletine	O	O
and	and	O	O
tocainide	tocainide	O	O
,	,	O	O
and	and	O	O
all	all	O	O
three	three	O	O
drugs	drugs	S_chemicals	O
have	have	O	O
central	central	O	B_disease
nervous	nervous	O	B_disease
system	system	O	I_disease
(	(	O	O
CNS	cns	O	O
)	)	O	O
stimulant	stimulant	O	O
action	action	O	O
.	.	O	O

Because	because	O	O
cibenzoline	cibenzoline	O	O
had	had	O	O
only	only	O	O
weak	weak	O	O
hypotensive	hypotensive	O	O
and	and	O	O
sinus	sinus	O	B_disease
node	node	O	I_disease
depressive	depressive	O	O
effects	effects	O	O
and	and	O	O
was	was	O	O
found	found	O	O
to	to	O	O
be	be	O	O
orally	orally	O	O
active	active	O	O
when	when	O	O
given	given	O	O
to	to	O	O
coronary	coronary	O	O
ligation	ligation	O	O
arrhythmia	arrhythmia	O	S_disease
dogs	dogs	O	O
,	,	O	O
its	its	O	O
clinical	clinical	O	O
usefulness	usefulness	O	O
is	is	O	O
expected	expected	O	O
.	.	O	O

